To include your compound in the COVID-19 Resource Center, submit it here.

Array reports updated data for encorafenib/binimetinib/Erbitux in metastatic CRC

Array BioPharma Inc. (NASDAQ:ARRY) reported updated response data for a combination regimen of encorafenib (LGX818), binimetinib (MEK162) and Erbitux cetuximab in the safety lead-in portion of the Phase III BEACON CRC trial to treat BRAF V600E-mutant metastatic colorectal cancer after one or two prior lines

Read the full 456 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE